I was off on the percentage. It is not .02% but is 2.6%. I still feel that is very low. I am sorry I went by memory...should have double checked first. Here is the quote and the link to the Clinical Trial Results.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701613/?log$=activity
"The percentage of patients developing antibodies to the human antibody adalimumab was low (7/269, 2.6%). It should be acknowledged that this small study lacked adequate statistical power to estimate accurately how often antibodies developed to adalimumab compared with placebo, or to explore whether concomitant immunosuppression with azathioprine, 6‐mercaptopurine, or methotrexate was protective. However, the results for the total number of patients exposed to adalimumab show that the immunogenicity of adalimumab in patients with Crohn's disease is modest. "
The above quote was in the last paragraph of the "Discussion" section of the report.
It has been a few months since I read the complete study (as well as the other studies) but can tell you it is full of really great info. If you take a look at the entire study it will even discuss what they have found for those taking multiple therapies as well as for those with RA as opposed to Crohn's.
